- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00085501
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time as chemotherapy or following chemotherapy.
PURPOSE: This randomized phase II trial is studying how well giving cetuximab at the same time as combination chemotherapy works compared to giving cetuximab after combination chemotherapy in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
OBJECTIVES:
Primary
- Compare overall survival of patients with selected stage IIIB or stage IV non-small cell lung cancer treated with concurrent vs sequential paclitaxel, carboplatin, and cetuximab.
Secondary
- Compare response rates (confirmed and unconfirmed, complete and partial) in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Correlate epidermal growth factor receptor polymorphisms and downstream biomarkers with response to cetuximab in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I (concurrent cetuximab): Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1, 8, and 15 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 8. Treatment repeats every 21 days for a total of 4 courses (12 weeks) in the absence of disease progression or unacceptable toxicity. Beginning on week 13, patients receive single-agent cetuximab IV over 1 hour once weekly in the absence of disease progression or unacceptable toxicity.
- Arm II (sequential cetuximab): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses (12 weeks) in the absence of disease progression or unacceptable toxicity. Beginning on week 13, patients receive single-agent cetuximab IV over 1 hour (over 2 hours on week 13 only) once weekly in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 180 patients (90 per treatment arm) will be accrued for this study within 9 months.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alaska
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Regional Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Stany Zjednoczone, 94705
- Alta Bates Comprehensive Cancer Center
-
Burlingame, California, Stany Zjednoczone, 94010
- Peninsula Medical Center
-
Duarte, California, Stany Zjednoczone, 91010
- City of Hope Comprehensive Cancer Center
-
Greenbrae, California, Stany Zjednoczone, 94904
- Sutter Health Western Division Cancer Research Group
-
Greenbrae, California, Stany Zjednoczone, 94904
- Marin Cancer Institute at Marin General Hospital
-
Hayward, California, Stany Zjednoczone, 94545
- Saint Rose Hospital
-
Livermore, California, Stany Zjednoczone, 94550
- Valley Memorial Hospital
-
Los Angeles, California, Stany Zjednoczone, 90033-0804
- USC/Norris Comprehensive Cancer Center and Hospital
-
Oakland, California, Stany Zjednoczone, 94602
- Highland General Hospital
-
Oakland, California, Stany Zjednoczone, 94609
- CCOP - Bay Area Tumor Institute
-
Oakland, California, Stany Zjednoczone, 94609
- Summit Medical Center
-
Palm Springs, California, Stany Zjednoczone, 92262
- Comprehensive Cancer Center at Desert Regional Medical Center
-
Roseville, California, Stany Zjednoczone, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stany Zjednoczone, 95816
- Sutter Cancer center
-
Sacramento, California, Stany Zjednoczone, 95819
- Mercy General Hospital
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Cancer Center
-
San Francisco, California, Stany Zjednoczone, 94118
- California Pacific Medical Center - California Campus
-
San Pablo, California, Stany Zjednoczone, 94806
- J.C. Robinson, M.D. Regional Cancer Center
-
Sana Rosa, California, Stany Zjednoczone, 95405
- CCOP - Santa Rosa Memorial Hospital
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80220
- Veterans Affairs Medical Center - Denver
-
Denver, Colorado, Stany Zjednoczone, 80204
- St. Anthony Central Hospital
-
Denver, Colorado, Stany Zjednoczone, 80217-3364
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
Fort Collins, Colorado, Stany Zjednoczone, 80524
- Poudre Valley Hospital
-
Montrose, Colorado, Stany Zjednoczone, 81401
- Montrose Memorial Hospital Cancer Center
-
Westminster, Colorado, Stany Zjednoczone, 80030
- St. Anthony North Hospital
-
Wheat Ridge, Colorado, Stany Zjednoczone, 80033
- Exempla Lutheran Medical Center
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Saint Joseph's Hospital of Atlanta
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- CCOP - Atlanta Regional
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Northside Hospital Cancer Center
-
Augusta, Georgia, Stany Zjednoczone, 30901
- Augusta Oncology Associates
-
Austell, Georgia, Stany Zjednoczone, 30106
- WellStar Cobb Hospital
-
Decatur, Georgia, Stany Zjednoczone, 30033
- Charles B. Eberhart Cancer Center at DeKalb Medical Center
-
Gainesville, Georgia, Stany Zjednoczone, 30501
- Northeast Georgia Medical Center
-
Lawrenceville, Georgia, Stany Zjednoczone, 30045
- Gwinnett Medical Center
-
Marietta, Georgia, Stany Zjednoczone, 30060
- Kennestone Cancer Center at Wellstar Kennestone Hospital
-
Riverdale, Georgia, Stany Zjednoczone, 30274
- Southern Regional Medical Center
-
Savannah, Georgia, Stany Zjednoczone, 31403
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
-
Valdosta, Georgia, Stany Zjednoczone, 31603
- Pearlman Comprehensive Cancer Center at South Georgia Medical Center
-
-
Hawaii
-
Aiea, Hawaii, Stany Zjednoczone, 96701
- Kapiolani Medical Center at Pali Momi
-
Honolula, Hawaii, Stany Zjednoczone, 96813
- Cancer Research Center of Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- OnCare Hawaii, Incorporated - Lusitana
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Queen's Cancer Institute at Queen's Medical Center
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Straub Clinic and Hospital, Incorporated
-
Honolulu, Hawaii, Stany Zjednoczone, 96817
- OnCare Hawaii, Incorporated - Kuakini
-
Honolulu, Hawaii, Stany Zjednoczone, 96817
- St. Francis Medical Center
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- St. Luke's Mountain States Tumor Institute - Boise
-
-
Illinois
-
Alton, Illinois, Stany Zjednoczone, 62002
- Saint Anthony's Hospital at Saint Anthony's Health Center
-
Maywood, Illinois, Stany Zjednoczone, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
Naperville, Illinois, Stany Zjednoczone, 60540
- Hematology Oncology Consultants Ltd.
-
Naperville, Illinois, Stany Zjednoczone, 60566
- Edward Hospital Cancer Center
-
-
Indiana
-
Beech Grove, Indiana, Stany Zjednoczone, 46107
- St. Francis Hospital and Health Centers
-
-
Iowa
-
Davenport, Iowa, Stany Zjednoczone, 52804
- Genesis Medical Center - West Campus
-
Davenport, Iowa, Stany Zjednoczone, 52803
- Genesis Regional Cancer Center at Genesis Medical Center
-
-
Kansas
-
Kansas City, Kansas, Stany Zjednoczone, 66160
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
Salina, Kansas, Stany Zjednoczone, 67401
- Salina Regional Health Center
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70112
- Tulane Cancer Center
-
Shreveport, Louisiana, Stany Zjednoczone, 71101
- Cancer Treatment Center at Christus Schumpert St. Mary Place
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02118
- Cancer Research Center at Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan Comprehensive Cancer Center
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106-0995
- St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital
-
Ann Arbor, Michigan, Stany Zjednoczone, 48100
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Stany Zjednoczone, 49017
- Cancer Care Center at Battle Creek Health System
-
Bay City, Michigan, Stany Zjednoczone, 48708
- Bay Regional Medical Center
-
Big Rapids, Michigan, Stany Zjednoczone, 49307
- Mecosta County General Hospital
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Josephine Ford Cancer Center at Henry Ford Health System
-
Flint, Michigan, Stany Zjednoczone, 48532
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Lacks Cancer Center at Saint Mary's Mercy Medical Center
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Spectrum Health Cancer Care - Butterworth Campus
-
Grand Rapids, Michigan, Stany Zjednoczone, 49506
- Metropolitan Hospital
-
Grand Rapids, Michigan, Stany Zjednoczone, 49506
- Spectrum Health Hospital - Blodgett Campus
-
Holland, Michigan, Stany Zjednoczone, 49423
- Holland Community Hospital
-
Mount Clemens, Michigan, Stany Zjednoczone, 48043
- Mount Clemens General Hospital
-
Muskegon, Michigan, Stany Zjednoczone, 49443
- Hackley Hospital
-
Petoskey, Michigan, Stany Zjednoczone, 49770
- Northern Michigan Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341-2985
- St. Joseph Mercy Hospital
-
Saginaw, Michigan, Stany Zjednoczone, 48601
- Seton Cancer Institute - Saginaw
-
Traverse City, Michigan, Stany Zjednoczone, 49684
- Munson Medical Center
-
Warren, Michigan, Stany Zjednoczone, 48903
- St. John Macomb Hospital
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- University of Mississippi Medical Center
-
Kessler AFB, Mississippi, Stany Zjednoczone, 39534-2519
- Keesler Medical Center - Keesler Air Force Base
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63701
- St. Francis Medical Center
-
Gape Girardeau, Missouri, Stany Zjednoczone, 63701
- Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
-
Joplin, Missouri, Stany Zjednoczone, 64804
- Freeman Cancer Institute at Freeman Health System
-
Springfield, Missouri, Stany Zjednoczone, 65804
- St. John's Regional Health Center
-
Springfield, Missouri, Stany Zjednoczone, 65807
- Hulston Cancer Center at Cox Medical Center South
-
St. Louis, Missouri, Stany Zjednoczone, 63141
- CCOP - St. Louis-Cape Girardeau
-
St. Louis, Missouri, Stany Zjednoczone, 63141
- David C. Pratt Cancer Center at St. John's Mercy
-
-
Montana
-
Billings, Montana, Stany Zjednoczone, 59101
- CCOP - Montana Cancer Consortium
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Great Falls Clinic
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Big Sky Oncology
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Sletten Regional Cancer Institute
-
-
New Jersey
-
Ridgewood, New Jersey, Stany Zjednoczone, 07450
- Valley Hospital - Ridgewood
-
-
New York
-
Glens Falls, New York, Stany Zjednoczone, 12801
- Adirondack Cancer Care
-
Rochester, New York, Stany Zjednoczone, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28203
- Blumenthal Cancer Center at Carolinas Medical Center
-
Goldsboro, North Carolina, Stany Zjednoczone, 27534
- Wayne Memorial Hospital, Incorporated
-
Hendersonville, North Carolina, Stany Zjednoczone, 28791
- Pardee Memorial Hospital
-
Rutherfordton, North Carolina, Stany Zjednoczone, 28139
- Rutherford Hospital
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44307
- McDowell Cancer Center at Akron General Medical Center
-
Cincinnati, Ohio, Stany Zjednoczone, 45220
- Tri-Health Good Samaritan Hospital
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Cleveland Clinic Taussig Cancer Center
-
Dayton, Ohio, Stany Zjednoczone, 45428
- Veterans Affairs Medical Center - Dayton
-
Dayton, Ohio, Stany Zjednoczone, 45405
- Grandview Hospital
-
Dayton, Ohio, Stany Zjednoczone, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Stany Zjednoczone, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, Stany Zjednoczone, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Stany Zjednoczone, 45429
- CCOP - Dayton
-
Independence, Ohio, Stany Zjednoczone, 44131
- Community Oncology Group - Independence
-
Kettering, Ohio, Stany Zjednoczone, 45429
- Charles F. Kettering Memorial Hospital
-
Mansfield, Ohio, Stany Zjednoczone, 44903
- MedCentral - Mansfield Hospital
-
Middletown, Ohio, Stany Zjednoczone, 45044
- Middletown Regional Hospital
-
Troy, Ohio, Stany Zjednoczone, 45373
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wooster, Ohio, Stany Zjednoczone, 44691
- Cleveland Clinic - Wooster
-
Wright-Patterson Afb, Ohio, Stany Zjednoczone, 45433-5529
- United States Air Force Medical Center Wright-Patterson
-
Xenia, Ohio, Stany Zjednoczone, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
Oregon
-
Bend, Oregon, Stany Zjednoczone, 97701
- St. Charles Medical Center
-
Glesham, Oregon, Stany Zjednoczone, 97030
- Legacy Mount Hood Medical Center
-
Milwaukie, Oregon, Stany Zjednoczone, 97222
- Providence Milwaukie Hospital
-
Portland, Oregon, Stany Zjednoczone, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, Stany Zjednoczone, 97225
- Providence St. Vincent Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97210
- Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Cancer Center at Providence Portland Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97227
- Institute of Oncology at Vilnius University
-
Salem, Oregon, Stany Zjednoczone, 97309
- Salem Hospital Regional Cancer Center
-
Tualatin, Oregon, Stany Zjednoczone, 97062
- Legacy Meridian Park Hospital
-
-
South Carolina
-
Anderson, South Carolina, Stany Zjednoczone, 29621
- Rose Ramer Cancer Clinic at Anderson Area Medical Center
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Florence, South Carolina, Stany Zjednoczone, 29506
- McLeod Regional Medical Center
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- CCOP - Greenville
-
Greenville, South Carolina, Stany Zjednoczone, 29601
- Bon Secours St. Francis Health System
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Greenville Hospital System Cancer Center
-
Spartanburg, South Carolina, Stany Zjednoczone, 29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
Spartanburg, South Carolina, Stany Zjednoczone, 29304
- CCOP - Upstate Carolina
-
-
Tennessee
-
Knoxville, Tennessee, Stany Zjednoczone, 37916
- Thompson Cancer Survival Center
-
-
Texas
-
Arlington, Texas, Stany Zjednoczone, 76012
- Arlington Cancer Center - Arlington
-
Fort Sam Houston, Texas, Stany Zjednoczone, 78234
- Brooke Army Medical Center
-
Lackland AFB, Texas, Stany Zjednoczone, 78236
- Wilford Hall Medical Center
-
Lubbock, Texas, Stany Zjednoczone, 79415
- UMC Southwest Cancer and Research Center
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute at University of Utah
-
-
Virginia
-
Danville, Virginia, Stany Zjednoczone, 24541
- Danville Regional Medical Center
-
Martinsville, Virginia, Stany Zjednoczone, 24115
- Memorial Hospital of Martinsville and Henry County
-
-
Washington
-
Bellingham, Washington, Stany Zjednoczone, 98225
- St. Joseph Hospital Community Cancer Center
-
Bremerton, Washington, Stany Zjednoczone, 98310
- Olympic Hematology and Oncology
-
Mt. Vernon, Washington, Stany Zjednoczone, 98273
- Cancer Care Center at Skagit Valley Hospital
-
Seattle, Washington, Stany Zjednoczone, 98104
- Harborview Medical Center
-
Seattle, Washington, Stany Zjednoczone, 98104
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Stany Zjednoczone, 98195
- University Cancer Center at University of Washington Medical Center
-
Seattle, Washington, Stany Zjednoczone, 98104
- Group Health Central Hospital
-
Seattle, Washington, Stany Zjednoczone, 98114
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Spokane, Washington, Stany Zjednoczone, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Stany Zjednoczone, 99204
- Providence Cancer Center at Sacred Heart Medical Center
-
Spokane, Washington, Stany Zjednoczone, 99207
- Providence Cancer Center at Holy Family Hospital
-
Vancouver, Washington, Stany Zjednoczone, 98668
- Southwest Washington Medical Center Cancer Center
-
Wenatchee, Washington, Stany Zjednoczone, 98801
- Central Washington Hospital
-
Wenatchee, Washington, Stany Zjednoczone, 98801
- Wenatchee Valley Clinic
-
Yakima, Washington, Stany Zjednoczone, 98902
- North Star Lodge Cancer Center
-
Yakima, Washington, Stany Zjednoczone, 98902
- Washington Hematology - Oncology Specialists
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of one of the following stages:
- Newly diagnosed selected stage IIIB disease (T4 lesion due to malignant pleural effusion, any N, M0)
- Newly diagnosed stage IV disease (any T, any N, M1)
- Recurrent stage IV disease after prior surgery or radiotherapy
The following subtypes are eligible:
- Adenocarcinoma
- Squamous cell carcinoma
- Large cell carcinoma
- Unspecified
Measurable disease by CT scan, MRI, x-ray, or physical exam
- Pleural effusions, ascites, or laboratory parameters are not acceptable as the only evidence of disease
- Not within prior radiotherapy field unless a new lesion is present
- Not within area of prior surgical resection
- No known brain metastases by CT scan or MRI
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9 mg/dL
Hepatic
- Bilirubin ≤ 2 times upper limit of normal (ULN)
- SGOT or SGPT ≤ 2 times ULN
- Alkaline phosphatase ≤ 2 times ULN
- No known acute hepatitis
Renal
- Creatinine ≤ ULN
- Creatinine clearance ≥ 50 mL/min
Cardiovascular
- No significant cardiac disease
- No uncontrolled hypertension
- No unstable angina
- No congestive heart failure
Other
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
- No active or uncontrolled infection
- No sensory neuropathy ≥ grade 2
- No known human anti-mouse antibodies
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy for NSCLC
- No prior chimeric or murine monoclonal antibody therapy
- No prior cetuximab
Chemotherapy
- No prior systemic chemotherapy for NSCLC
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- At least 3 weeks since prior radiotherapy and recovered
Surgery
- See Disease Characteristics
- At least 2 weeks since prior thoracic or major surgery and recovered
Other
- No prior gefitinib or other investigational agents that target the epidermal growth factor receptor pathway
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Aktywny komparator: 2
|
Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2. Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14. Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2 Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1 Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4. Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1. |
Aktywny komparator: 1
|
Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2. Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14. Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2 Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1 Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4. Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Select a regimen based on overall survival
Ramy czasowe: From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
To select a regimen based on overall survival via a Phase II selection design of chemotherapy in conjunction with cetuximab (concurrent vs. sequential) for Phase III testing against chemotherapy alone in Stage IIIB and Stage IV non-small cell lung cancer.
|
From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
Response rate (confirmed and unconfirmed, complete and partial response)
Ramy czasowe: From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
To evaluate response rates (confirmed and unconfirmed, complete and partial) of patients with selected Stage IIIB and Stage IV NSCLC treated with paclitaxel and carboplatin with concurrent cetuximab or paclitaxel and carboplatin followed by cetuximab.
|
From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
Toxicities
Ramy czasowe: From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
To evaluate the toxicities of the two treatment regimens in patients with selected Stage IIIB and Stage IV NSCLC.
|
From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Correlation of epidermal growth factor receptor polymorphisms and downstream biomarkers with response
Ramy czasowe: At prestudy
|
To conduct exploratory molecular correlative studies of the EGFR-HER signaling pathways examining activated phosphoproteins, oncogenic mutations and rates of proliferation and apoptosis in patient tissues (see S9925 for details).
|
At prestudy
|
Evaluate EGFR polymorphisms
Ramy czasowe: At prestudy and week 5
|
To evaluate EGFR polymorphisms as a potential correlate for response to cetuximab (see S9925 for details).
|
At prestudy and week 5
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Karen Kelly, MD, University of Colorado, Denver
- Główny śledczy: Roy S. Herbst, MD, PhD, M.D. Anderson Cancer Center
- Główny śledczy: David R. Gandara, MD, University of California, Davis
Publikacje i pomocne linki
Publikacje ogólne
- Franklin WA, Gandara DR, Kim ES, et al.: SWOG S0342 and S0536: expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 27 (Suppl 15): A-11076, 2009.
- Mack PC, Holland WS, Redman M, et al.: KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. [Abstract] J Clin Oncol 27 (Suppl15): A-8022, 2009.
- Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10;26(20):3351-7. doi: 10.1200/JCO.2007.14.0111.
- Herbst RS, Chansky K, Kelly K, et al.: A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. [Abstract] J Clin Oncol 25 (Suppl 18): A-7545, 395s, 2007.
- Kelly K, Herbst RS, Crowley JJ, et al.: Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): a randomized phase II selectional trial SWOG 0342. [Abstract] J Clin Oncol 24 (Suppl 18): A-7015, 367s, 2006.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Oddechowego
- Nowotwory
- Choroby płuc
- Nowotwory według lokalizacji
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Nowotwory płuc
- Rak, płuco niedrobnokomórkowe
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwnowotworowe
- Modulatory tubuliny
- Środki antymitotyczne
- Modulatory mitozy
- Środki przeciwnowotworowe, Fitogenne
- Środki przeciwnowotworowe, immunologiczne
- Karboplatyna
- Paklitaksel
- Cetuksymab
Inne numery identyfikacyjne badania
- CDR0000370806
- U10CA032102 (Grant/umowa NIH USA)
- S0342 (Inny identyfikator: SWOG)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak płuc
-
Janssen Pharmaceutical K.K.RekrutacyjnyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Republika Korei, Japonia
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Aktywny, nie rekrutującyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrutacyjnyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)Aktywny, nie rekrutującyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Republika Korei
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWycofanePrzerzutowy rak nerkowokomórkowy | Rak nerkowokomórkowy IV stopnia AJCC v8 | Rak brodawkowaty nerki | Zbieranie raka przewodów | Nieoperacyjny rak nerki | Dziedziczna leiomyomatoza i rak nerkowokomórkowy | Jasnokomórkowy brodawkowaty nowotwór nerki | Dziedziczny rak brodawkowaty nerki | Niesklasyfikowany... i inne warunkiStany Zjednoczone
Badania kliniczne na cetuximab
-
Istituto Scientifico Romagnolo per lo Studio e...ZakończonyRak jelita grubego z przerzutamiWłochy
-
Associazione Volontari Pazienti OncologiciMario Negri Institute for Pharmacological ResearchZakończonyRak płaskonabłonkowy głowy i szyiWłochy
-
Glycotope GmbHZakończonyGuz lity, dorosłyNiemcy, Włochy, Hiszpania